SA
TEVA icon

Scarborough Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Scarborough Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43
Closed -$1.29K – 626
2026
Q1 		$1.29K Buy
+43
New +$1.38K ﹤0.01% 626
2024
Q1 		– Sell
-43
Closed -$449 – 687
2023
Q4 		$449 Buy
+43
New +$401 ﹤0.01% 666

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Scarborough Advisors's TEVA Position: Q2 2026 in Review

Scarborough Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 43 shares — an estimated $1.29K sold.

Scarborough Advisors first reported a position in TEVA in Q4 2023 and held it in 2 quarters. The position peaked at $1.29K in Q1 2026. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Scarborough Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 43 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.29K.
  • Scarborough Advisors first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Scarborough Advisors's Teva Pharmaceuticals position peaked at $1.29K in Q1 2026.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.